Effect of cinacalcet therapy on renal anemia in hemodialysis patients with secondary hyperparathyroidism

DOI Web Site 45 References
  • Otsubo Shigeru
    Department of Blood Purification, Sangenjaya Hospital Department of Nursing, Faculty of Human Care, Tohto College of Health Sciences
  • Yajima Aiji
    Towa Hospital
  • Naito Masayo
    Department of Blood Purification, Sangenjaya Hospital Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Ishihara Miwa
    Department of Blood Purification, Sangenjaya Hospital Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Ueda Syuitsu
    Department of Blood Purification, Sangenjaya Hospital
  • Sugimoto Hisayuki
    Department of Blood Purification, Sangenjaya Hospital
  • Otsubo Kimiko
    Department of Blood Purification, Sangenjaya Hospital
  • Kimata Naoki
    Department of Blood Purification, Kidney Center, Tokyo Women's Medical University
  • Uchida Keiko
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
  • Akiba Takashi
    Department of Blood Purification, Kidney Center, Tokyo Women's Medical University
  • Nitta Kosaku
    Department of Medicine, Kidney Center, Tokyo Women's Medical University

Bibliographic Information

Other Title
  • 血液透析患者における二次性副甲状腺機能亢進症に対するシナカルセト投与が貧血に及ぼす影響
  • ケツエキ トウセキ カンジャ ニ オケル 2ジセイ フクコウジョウセン キノウ コウシンショウ ニ タイスル シナカルセト トウヨ ガ ヒンケツ ニ オヨボス エイキョウ

Search this article

Abstract

Secondary hyperparathyroidism (SHPT) is known to inhibit the erythropoiesis. To determine the effect of cinacalcet treatment on renal anemia, we investigated the response to erythropoiesis-stimulating agents (ESA) in hemodialysis patients started on cinacalcet. Twenty patients on maintenance hemodialysis started on treatment with cinacalcet were enrolled in this study. Serum levels of intact parathyroid hormone (i-PTH), albumin, calcium, phosphorus, alkaline phoshatase, c-reactive protein (CRP), iron, total iron-binding capacity and hemoglobin were measured before and at 1, 4, 8 and 12 months after the start of cinacalcet therapy. Darbepoetin Alfa (DPO) was used as the ESA. We also compared the required dose of ESA. Cinacalcet therapy resulted in an immediate decrease of the serum i-PTH from the pre-treatment level of 854±293 pg/mL to 503±421 pg/mL (p<0.0001) at 1 month and a further decrease to 283±243 pg/mL (p<0.0001) at 12 months. There were no significant changes in serum albumin or CRP levels or of the transferrin saturation or hemoglobin level in the patients. The dose of DPO was gradually decreased. Compared with the pre-treatment dose (24.0±16.7 μg/week), the dose of DPO was significantly lower at 8 months (15.0±20.1 μg/week, p<0.05) and at 12 months (14.0±16.4 μg/week, p<0.05). Addition of cinacalcet to conventional SHPT therapy may be associated with an improved response to ESA administered for the treatment of renal anemia.

Journal

References(45)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top